Precision Medicine in Oncology

The AJMC® Precision Medicine in Oncology compendium is a comprehensive resource for clinical news and expert insights for molecular profiling of tumors.

Latest News

There was significant variability in test frequency and detection rates among patients with AML and MDS. | Image credit: Saiful52-stock.adobe.com
Gaps in Molecular Testing Rates, Targeted Treatment Persist in MDS, AML

July 11th 2025

There are molecular testing gaps in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment, highlighting the need for improved testing and targeted therapy integration.

DNA | Image credit: NHS
Breast Cancer and the Use of Predictive Genomics

June 18th 2025

May 2024 News From Strategic Alliance Partners
May 2024 News From Strategic Alliance Partners

May 20th 2024

New KRYSTAL-1 Data Show 90% Intracranial Disease Control Rate in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases
New KRYSTAL-1 Data Show 90% Intracranial Disease Control Rate in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases

August 16th 2023

ASCO 2023 logo
ASCO 2023: Solid Tumors

July 31st 2023

More News

Site Logo
March 22nd 2019

NCCN Prostate Cancer Update Emphasizes Germline Testing

Mary Caffrey
Germline testing at diagnosis, along with tumor testing, have the potential to identify candidates for investigational poly (ADP-ribose) polymerase (PARP) inhibitors, and updated guidelines call for their expanded use.
Feyi Olopade Ayodele Highlights How CancerIQ Helps With Genetic Testing
March 22nd 2019

Feyi Olopade Ayodele Highlights How CancerIQ Helps With Genetic Testing

CancerIQ is reducing barriers that make it difficult to utilize genetic testing to predict or pre-empt a patient’s cancer diagnosis, explained Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
Dr John Ward on Conversations With Patients After Multigene Testing
March 22nd 2019

Dr John Ward on Conversations With Patients After Multigene Testing

Multigene testing provides a lot of information that providers have to be familiar with in order to adequately explain it to their patients, said John H. Ward, MD, Huntsman Cancer Institute at the University of Utah.
PD-L1 Testing "Name of the Game" in First-Line Treatment of NSCLC
March 22nd 2019

PD-L1 Testing "Name of the Game" in First-Line Treatment of NSCLC

Mary Caffrey
Guideline updates discussed Thursday at the 2019 National Comprehensive Cancer Network Annual Conference reflect recent practice-changing clinical trials involving pembrolizumab and chemotherapy.
Genomic Testing Can Reduce Costs by $6600 for Certain Patients With Breast Cancer
March 20th 2019

Genomic Testing Can Reduce Costs by $6600 for Certain Patients With Breast Cancer

Laura Joszt, MA
Patients with high-risk breast cancer who receive a 21-gene assay genomic test may be able to avoid chemotherapy and ultimately save a significant amount of money.
Study Links Presence of Oral Bacteria in Pancreas to Severity of Tumors
March 14th 2019

Study Links Presence of Oral Bacteria in Pancreas to Severity of Tumors

Mary Caffrey
Finding a less invasive way of determing if pancreatic cysts are likely to become cancerous would be good for patients and less taxing on the healthcare system.
The Increasing Relevancy of MRD Testing in Blood Cancers
March 12th 2019

The Increasing Relevancy of MRD Testing in Blood Cancers

Laura Joszt, MA
Minimal residual disease (MRD) testing is the future of diagnostics and monitoring for cancer, according to some experts. Not only can MRD determine the depth of response to a treatment, but it can also be used to determine treatment strategies.
Liquid Biopsy Study Shows Test Accurately Guides Care in NSCLC When Tissue Unavailable
March 8th 2019

Liquid Biopsy Study Shows Test Accurately Guides Care in NSCLC When Tissue Unavailable

Mary Caffrey
Not having enough tissue is often a problem in precision medicine. The senior author of a new study said a liquid biopsy could become a new standard.
Detecting MRD During and After Hematopoietic Stem Cell Transplantation
March 5th 2019

Detecting MRD During and After Hematopoietic Stem Cell Transplantation

Laura Joszt, MA
Two abstracts presented at the Transplantation and Cellular Therapy Meetings analyzed the detection of minimal residual disease during and after hematopoietic stem cell transplantation.
Topline Results for Olaparib Maintenance Show Improved PFS in BRCA-Mutated Pancreatic Cancer
March 1st 2019

Topline Results for Olaparib Maintenance Show Improved PFS in BRCA-Mutated Pancreatic Cancer

Mary Caffrey
AstraZeneca and Merck will present full results at a future meeting; Myriad Genetics will file a supplemental application for its companion diagnostic.
Using NGS to Assess Minimal Residual Disease Better Predicts Outcomes in AML
February 26th 2019

Using NGS to Assess Minimal Residual Disease Better Predicts Outcomes in AML

Laura Joszt, MA
A high proportion of patients with acute myeloid leukemia (AML) who achieve a negative minimal residual disease (MRD) status still relapse, indicating a more sensitive method of detecting MRD is needed.
PET Scans Could Identify Patients With Breast Cancer Who May Be Able to Avoid Chemotherapy
February 22nd 2019

PET Scans Could Identify Patients With Breast Cancer Who May Be Able to Avoid Chemotherapy

Laura Joszt, MA
Researchers have used positron emission tomography scans to identify which patients with a type of human epidermal growth factor receptor 2–positive breast cancer might benefit most from targeted agents alone and can be spared chemotherapy.
Personalized Medicines Account for 42% of All Drug Approvals in 2018
February 21st 2019

Personalized Medicines Account for 42% of All Drug Approvals in 2018

Samantha DiGrande
More than one-third of the therapies the FDA approved in the last 2 years includes information on the label identifying patients would benefit the most or experience fewer side effects, found a recently published report from the Personalized Medicine Coalition.
Breast Surgeons Seek Genetic Testing for All Patients With Breast Cancer
February 19th 2019

Breast Surgeons Seek Genetic Testing for All Patients With Breast Cancer

Mary Caffrey
The update follows a study published in November that found almost no difference in the frequency of mutations between patients with breast cancer who met National Comprehensive Cancer Network guidelines and those who didn't.
Dr Thomas Martin Outlines How MRD Testing Is Being Used
February 16th 2019

Dr Thomas Martin Outlines How MRD Testing Is Being Used

Currently, minimal residual disease testing is being used for prognostication not for treatment decisions, explained Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco (UCSF); co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center.
Patients With Relapsed/Refractory MM More Likely to Have Sustained MRD on Daratumumab
February 15th 2019

Patients With Relapsed/Refractory MM More Likely to Have Sustained MRD on Daratumumab

Laura Joszt, MA
Minimal residual disease (MRD) is a strong prognosticator of cancer outcomes, and recent research found that patients with relapsed/refractory multiple myeloma (MM) are more likely to achieve MRD on daratumumab than on a standard of care alone.
Site Logo
February 14th 2019

Moving Toward the "Tipping Point" for Transformation in Cancer Care

Mary Caffrey
Andrew Pecora, MD, FACP, CPE, recently visited Evidence-Based OncologyTM to discuss the progress of COTA’s, a company created in 2011 to develop technology that Pecora said is poised to transform cancer care delivery by helping oncologists and other specialists make decisions that will yield the best outcomes in the most cost-effective way, all at the point of care.
MRD Can't Predict Response in Early Days of Intensive AML Therapy, Study Says
February 9th 2019

MRD Can't Predict Response in Early Days of Intensive AML Therapy, Study Says

David Bai, PharmD
Molecular minimal residual disease (MRD) testing during the first 4 days of induction therapy does not differentiate responders and nonresponders and should not be used in predicting clinical response for patients with acute myeloid leukemia (AML), according to the results from a recent study.
VA Contract Makes Foundation Medicine Oncology Tests Available to Veterans
February 5th 2019

VA Contract Makes Foundation Medicine Oncology Tests Available to Veterans

Laura Joszt, MA
Foundation Medicine announced that it has won a nationwide contract from the Department of Veterans Affairs National Precision Oncology Program. The contract covers all of Foundation Medicine’s tests.
Predicting AML Outcomes by Monitoring Minimal Residual Disease
February 2nd 2019

Predicting AML Outcomes by Monitoring Minimal Residual Disease

Laura Joszt, MA
Abstracts presented at the 60th American Society of Hematology Annual Meeting & Exposition looked at how monitoring minimal residual disease can help predict outcomes in acute myeloid leukemia (AML).
Review Identifies Potential Predictive Biomarkers in Colorectal Cancer
February 2nd 2019

Review Identifies Potential Predictive Biomarkers in Colorectal Cancer

David Bai, PharmD
A recent review outlined a vast array of biomarkers that may have clinical implications on the treatment and prognosis of colorectal cancer (CRC).
Dr Elizabeth Griffiths Discusses Barriers to Genetic Testing in AML
January 30th 2019

Dr Elizabeth Griffiths Discusses Barriers to Genetic Testing in AML

The biggest barrier to molecular profile testing right now is a financial one, explained Elizabeth Griffiths, MD, associate professor of oncology, department of medicine, Roswell Park Comprehensive Cancer Center
Undetectable MRD May Be Used to Develop Early Intervention Strategies in Patients With CLL
January 26th 2019

Undetectable MRD May Be Used to Develop Early Intervention Strategies in Patients With CLL

David Bai, PharmD
A study of 3 assessments for patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab are examined.
Diagnostic Test Assessing MRD in Patients With MM and ALL Receives Medicare Coverage
January 25th 2019

Diagnostic Test Assessing MRD in Patients With MM and ALL Receives Medicare Coverage

Laura Joszt, MA
The first and only test authorized by the FDA to detect and monitor minimal residual disease (MRD) in multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL) has received coverage for Medicare patients.
Dr Jeff Sharman on Using Precision Medicine to Treat CLL
January 24th 2019

Dr Jeff Sharman on Using Precision Medicine to Treat CLL

Jeff Sharman, MD, medical oncologist, Willamette Valley Cancer Institute and Research Center; medical director, The US Oncology Network, explains how personalized medicine has changed the way physicians think about treatment for patients with chronic lymphocytic leukemia (CLL).
Detection of Minimal Residual Disease Predicts Outcomes, Can Guide Strategies in AML
January 18th 2019

Detection of Minimal Residual Disease Predicts Outcomes, Can Guide Strategies in AML

Laura Joszt, MA
Minimal residual disease in patients with acute myeloid leukemia (AML) can be a powerful predictor of outcomes and a useful guide of treatment strategies.
ctDNA Alone Not a Useful Biomarker of Multiple Myeloma Disease Status, Study Says
January 16th 2019

ctDNA Alone Not a Useful Biomarker of Multiple Myeloma Disease Status, Study Says

David Bai, PharmD
There is a lack in correlation between circulating tumor DNA (ctDNA) and bone marrow for minimal residual disease (MRD) by next generation sequencing (NGS) using immunoglobulin genes in patients with multiple myeloma, according to results of a recent study.
Dr Elizabeth Griffiths on Biomarkers, Mutational Events That Drive Treatment Choice in AML
January 15th 2019

Dr Elizabeth Griffiths on Biomarkers, Mutational Events That Drive Treatment Choice in AML

Elizabeth Griffiths, MD, associate professor of oncology, department of medicine, Roswell Park Comprehensive Cancer Center discusses which biomarkers and mutational events help determine if a patient would likely benefit from a traditional therapy or if they are more suitable for a clinical trial or upfront allogeneic transplantation.
Phase 2 Study of Combo Therapy Shows Promise for Patients With Mantle Cell Lymphoma
January 9th 2019

Phase 2 Study of Combo Therapy Shows Promise for Patients With Mantle Cell Lymphoma

David Bai, PharmD
A phase 2 trial demonstrated that the regimen of rituximab, bortezomib, bendamustine, and dexamethasone is a viable treatment option for older patients with mantle cell lymphoma (MCL), and highlighted the usefulness of using minimal residual disease (MRD) to guide early and late clinical decisions.
Using Precision Medicine to Treat the Long Arc of Disease
January 9th 2019

Using Precision Medicine to Treat the Long Arc of Disease

Laura Joszt, MA
In the past year, there have been tremendous advancements in precision medicine, and the big upfront investments are starting to come to fruition, according to panelists at the 37th Annual JP Morgan Healthcare Conference, held January 7-10 in San Francisco, California.
<1
...
891011121314>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo